[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Helsinki University Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":665},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,45,69,98,126,156,183,209,233,253,283,306,330,355,376,398,420,444,472,503,536,564,593,614,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641729","execise-intervention-in-adult-severe-asthma-100641729",false,"NCT07655037","Execise Intervention in Adult Severe Asthma","Exercise Intervention in Severe Asthma: a Randomized Controlled Trial in Adults on Biological Treatment for Asthma","Inclusion Criteria:\n\n* Age over 18 years\n* Physician-diagnosed severe asthma defined with the GINA criteria and with a decision to initiate biological treatment (omalizumab, mepolizumab, benralizumab, dupilumab or tezepelumab) for severe asthma\n\nExclusion Criteria:\n\n* Upcoming major surgery\n* Acute musculoskeletal disease which unables regular exercise\n* Inability to commit to the appointments and the exercise plan due to exhaustion or fatigue\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Physical activity has been shown to improve asthma control in individuals with asthma. Patients with severe asthma frequently experience exacerbations, which often result in a physically inactive lifestyle. The investigators therefore hypothesize that patients with severe asthma who initiate biological therapy may particularly benefit from increased physical activity, both in terms of exercise capacity and asthma control.\n\nThe aim of this study is to determine whether an individually tailored exercise program improves exercise capacity and asthma control in patients with severe asthma. Additionally, the study evaluates the effects of the intervention on asthma symptoms, frequency of exacerbations, lung function, quality of life, and body composition.\n\nThe primary outcome is the change in exercise tolerance, measured as peak oxygen uptake during cardiopulmonary exercise testing.\n\nSecondary outcomes include asthma symptoms (proportion of patients reporting improvement based on the Asthma Control Test), frequency of exacerbations, changes in lung function (FVC and FEV1), asthma-related quality of life (AQLQ), and changes in body composition (body mass index and waist circumference).\n\nAt baseline, all participants undergo fitness assessments, including cardiopulmonary exercise testing and muscle strength tests. Participants are then randomized into two groups. The intervention group receives an individually tailored 6-month exercise program designed by a sports medicine physician and a physiotherapist based on baseline fitness level. The control group receives standard advice to increase physical activity. Asthma medication is managed according to standard clinical practice in both groups.\n\nFitness assessments are repeated at 6 months for all participants, and asthma control is evaluated at 6 and 12 months",[27,28],"Severe Asthma","Asthma",[30,31],"severe asthma","biological treatment","RECRUITING","2026-06-15",{"date":35,"type":36},"2026-06-17","ACTUAL",{"date":38,"type":36},"2026-03-18",{"date":40,"type":21},"2028-10",{"name":42,"class":43},"Helsinki University Central Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100566046","protective-ileostomy-versus-protective-colostomy-in-anterior-rectal-resection-100566046","NCT06650085","Protective Ileostomy Versus Protective Colostomy in Anterior Rectal Resection","PROtective ileoStomy Versus ProtectivE Colostomy in Anterior Rectal resectIon - a Multicenter, Open-label, Randomized conTrolled studY (PROSPERITY)","PROSPERITY","Inclusion Criteria: Patients undergoing anterior resection (resection of the rectum and colorectal or coloanal anastomosis) due to a rectal tumour and a protective stoma is planned.\n\nThe exclusion criteria are: (1) patient already having a stoma (or another stoma made during surgery), (2) technical inability to create ileo- or colostomy (e.g. previous bowel resection, anatomical factors), (3) age \\\u003C18 years, (4) inadequate ability to co-operate.",{"count":54,"type":21},350,[24],"Loop ileostomy and loop colostomy are both used as protective stomas after anterior resection. There is a lack of evidence on the superiority of loop ileostomy versus loop colostomy. This is a multicenter, open-label, superiority, individually randomized controlled trial including patients undergoing anterior rectal resection with primary anastomosis and a protective stoma. Patients scheduled for anterior rectal resection are randomized 1:1 to loop ileostomy or loop colostomy intraoperatively. Primary outcome is cumulative stoma-related adverse events within 60 days post-primary surgery (scored using Comprehensive Complication Index (CCI)).",[58,59],"Stoma Colostomy","Stoma Ileostomy","2026-06-05",{"date":62,"type":36},"2026-06-09",{"date":64,"type":36},"2025-10-06",{"date":66,"type":21},"2033-10",{"name":42,"class":43},3,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100643750","ionized-calcium-and-bleeding-in-cardiac-surgery-100643750","NCT07634042","Ionized Calcium and Bleeding in Cardiac Surgery","Plasma Ionized Calcium and Perioperative Bleeding in Cardiac Surgery.","Inclusion Criteria:\n\n* age 18-100 years\n* open-heart surgery with cardiopulmonary bypass (surgery with a main procedure code in the NCSP classification F category, \"Heart and Great Vessels of the Thorax\", performed on extracorporeal perfusion, procedure code FXA00)\n* between January 2021 and March 2026\n\nExclusion Criteria:\n\n* organ transplants (procedure code FQ)\n* hemophilia, von Willebrand disease, or platelet function disorders (ICD-10 codes D65-D69)\n* essential thrombocythemia (ICD-10 code D75.2)","100 Years",{"count":78,"type":21},4300,"OBSERVATIONAL","This retrospective study investigates the association between perioperative plasma ionized calcium concentration and perioperative bleeding in open-heart surgery. Excluding patients who meet exclusion criteria, the study will include all applicable adult patients who underwent cardiac surgery at Helsinki University Hospital between January 2021 and March 2026. As clinical routine, during both cardiac surgery and the subsequent intensive care period, multiple blood gas analyses were performed, including measurements of plasma ionized calcium concentration. Time-weighted averages of all measurements will be calculated across different phases of surgery (pre-CPB, on -CPB, post-CPB) and the first 24 hours of ICU stay (0-6 h, 6-12 h, 12-24 h). Perioperative bleeding will be assessed using the Universal Definition of Perioperative Bleeding (UDPB) classification validated for cardiac surgery. In addition to chest drain output, this classification accounts for blood products administered to treat bleeding (red blood cells, platelets, and fresh frozen plasma), pharmacological coagulation factor concentrates (fibrinogen\u002Fcryoprecipitate, PCC, aFVIIa) and surgical interventions (open sternum, resternotomy). The association between plasma ionized calcium and UDPB class will be assessed with regression models. The primary analysis will be the association between time-weighted mean plasma ionized calcium level during the post-CPB phase as a continuous variable and dichotomous UDPB (UDPB 3-4 vs. UDPB 0-2) in patients who did not receive blood products during the post-CPB phase. One secondary and two sensitivity analyses will be performed",[82],"Cardiac Surgery Subjects",[84,85,86,87,88],"cardiac surgery","cardiopulmonary bypass","plasma ionized calcium","bleeding","perioperative bleeding","NOT_YET_RECRUITING","2026-06-03",{"date":92,"type":36},"2026-06-08",{"date":94,"type":21},"2026-06-01",{"date":96,"type":21},"2029-12-31",{"name":42,"class":43},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100638119","finnish-carpal-tunnel-surgery-study-100638119","NCT07614425","Finnish Carpal Tunnel Surgery Study","Finnish Carpal Tunnel Study - a Randomised, Placebo-surgery Controlled Trial","FINCATS","Inclusion Criteria:\n\n* Age 18-75 years\n* Clinical manifestations of carpal tunnel syndrome: paresthesia and \u002For hypoesthesia in the distribution of the median nerve, possibly pain\n* Electrodiagnostically (ENMG or ENEG) verified compression of the median nerve at the carpal tunnel in the wrist, performed no more than a year before recruitment.\n* Duration of symptoms 3 months or longer\n* Patient living independently\n* Patient has not responded to the use of a resting splint supporting the wrist, nor to other possible conservative forms of treatment\n* Patient able and willing to give consent\n* The patient is willing to undergo surgical treatment for carpal tunnel syndrome.\n* The patient has access to a device that can be used to complete electronic symptom questionnaires.\n\nExclusion Criteria:\n\n* Work disability\n* Clinical findings of Abductor Pollicis Brevis atrophy\n* Symptoms and Electrodiagnostic findings of some other peripheral neural entrapment than carpal tunnel syndrome\n* Rheumatoid arthritis or other forms of systemic inflammatory disease\n* Diagnosed dementia\n* Neurologic disorders affecting the function of the hand\n* Other untreated systemic disorders or diseases with poor therapeutic balance: hypertension, epilepsy, pulmonary or cardiac disease, liver or renal insufficiency, diabetes mellitus, hypothyroidism, psychiatric disease\n* Other causes of pain and paresthesia in the hand\n* Previous trauma of the hand or wrist (e.g. distal radius fracture), which has resulted in compromised hand function\n* Previous carpal tunnel release in either hand\n* Previous nerve injury to the upper limb or cervical spine","75 Years",{"count":108,"type":21},180,[24],"Carpal tunnel syndrome (CTS) is a common condition caused by pressure from a ligament on a nerve in the wrist, leading to pain, numbness, and weakness in the hand. Surgery to cut the ligament is often recommended when non-surgical treatments do not provide sufficient symptom relief, but it is unclear how much of the improvement is due to the surgery itself versus natural recovery or placebo effects.\n\nThe FINCATS study will compare standard carpal tunnel surgery with a placebo procedure in which the ligament is not cut. Participants and the healthcare staff caring for them after the procedure will not know which procedure was performed. The study's main question is whether cutting the ligament provides greater symptom relief than a placebo procedure. In addition, eligible patients who are not willing to participate in randomized setting are invited to join a parallel observational group. Participants in this observational group are treated within usual care pathway.\n\nParticipants in both the randomized and observational group will be followed for five years to assess symptom improvement, hand function, pain, quality of life, and any side effects. The goal is to provide reliable evidence to help patients and doctors make informed decisions about treatment.",[112],"Carpal Tunnel Syndrome",[114,115,116,117,118],"Randomised controlled trial","Placebo-controlled trial","Surgery","Carpal tunnel syndrome","Carpal tunnel release",{"date":90,"type":36},{"date":121,"type":21},"2026-06-11",{"date":123,"type":21},"2035-12-31",{"name":42,"class":43},2,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":44},"100625154","findisc-pain-finnish-discectomy-trial-on-the-benefits-and-harms-of-surgery-in-patients-with-lumbar-disc-herniation-100625154","NCT07418944","FINDISC-Pain, Finnish Discectomy Trial on the Benefits and Harms of Surgery in Patients With Lumbar Disc Herniation","FINDISC-Pain, Finnish Discectomy Trial - a Randomised, Placebo-surgery Controlled Trial. An Efficacy Trial Designed to Prove That Discectomy Can Work.","FINDISC-Pain","Inclusion Criteria:\n\n* Age 18-60 years\n* Diagnosed unilateral lower extremity radiculopathy (sciatica) secondary to lumbar disc herniation (LDH)\n* Single LDH at the level of L3\u002F4, L4\u002F5 or L5\u002FS1 on magnetic resonance imaging\n* Symptom duration minimum 6 weeks\n* NRS worst leg pain 5 or higher\n* Patient has not responded to at least one form of non-operative care\n* Patient willing to undergo surgery\n* Patient willing and able to give consent and comply with study procedures\n* Sufficient proficiency in the language of the study site to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Doubtful nerve root compression\n* Spinal stenosis or any other confounding spinal condition\n* Far lateral disc herniation\n* Serious neurological deficit\n* Previous spinal surgery\n* Any contraindication to MRI\n* BMI \\> 35 or lumbar subcutaneous fat \\> 50 mm as determined from the MRI\n* ASA classification \\> 2\n* Being pregnant","60 Years",{"count":136,"type":21},122,[24],"The FINDISC trial studies whether common back operation, microdiscectomy, is effective and safe for treating sciatica caused by a lumbar disc herniation. The study includes people whose leg pain has not improved after at least six weeks of non-surgical treatment.\n\nThe FINDISC trial aims to recruit and randomly allocate 122 participants to receive either the actual operation (discectomy) or a placebo (sham) surgery. The placebo (sham) procedure involves anesthesia and an approach similar to the real operation, but no removal of disc material or bone. Participants and healthcare staff, excluding the surgical team, will not know which treatment was given. The study compares pain relief, recovery, daily functioning, quality of life, and harms between the two groups.\n\nThe goal of the study is to provide reliable evidence to help patients and clinicians decide whether microdiscectomy offers meaningful benefits compared with placebo surgery.",[140,141],"Lumbar Disc Herniation With Radiculopathy","Sciatica",[143,144,116,145,146,147],"randomized controlled trial","Placebos","placebo-controlled trial","discectomy","patient acceptable symptoms state","2026-05-20",{"date":150,"type":36},"2026-05-22",{"date":152,"type":36},"2026-02-19",{"date":154,"type":21},"2030-12",{"name":42,"class":43},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100628234","phase-3-fmt-capsules-for-rcdi-100628234","NCT07458984","FMT Capsules for rCDI","Fecal Microbiota (FMT) Oral Capsules in the Treatment of Recurrent Clostridioides Difficile Infection","FMT CAP CDI","Inclusion Criteria:\n\n* At least twice recurrent CDI\\*\n* Patient has had CDI-related diarrhea during infections (3 or more Bristol Stool Form Scale type 6-7 stools)\n* Other causes of diarrhea have been excluded based on clinical data\n* Age over 18 years\n* Remission of symptoms during antibiotic course (metronidazole, vancomycin or fidaxomicin)\n* No other antibiotic courses\n* Able to sign the consent form or accept it electronically via Suomi.fi identification\n\n  * definition of recurrent CDI: CDI-compatible symptoms and a positive stool test Clostridioides difficile nucleic acid test within 12 weeks of the previous infection\n\nExclusion Criteria:\n\n* Pregnancy\n* Continuous need for antibiotic treatment\n* Previous anaphylactic reactions to any food\n* Gastroparesis\n* Life-threatening fulminant CDI\n* Life expectancy less than 1 year\n* Inability to sign a consent form for the study",{"count":165,"type":21},76,[167],"PHASE3","Double blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.",[170,171],"Clostridioides Difficile Infection Recurrence","FMT",[173,171,174],"Clostridioides Difficile infection","Capsule","2026-04-24",{"date":177,"type":36},"2026-04-29",{"date":179,"type":36},"2026-04-25",{"date":181,"type":21},"2030-12-31",{"name":42,"class":43},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":125},"100625515","the-impact-of-early-automated-insulin-delivery-aid-therapy-on-diabetes-control-and-comorbidities-and-cost-effectiveness-of-aid-treatment-100625515","NCT07423637","The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment","The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment - a Prospective, Randomized, Controlled Study on Pediatric Patients With Type 1 Diabetes","Inclusion Criteria:\n\n* Children and adolescents aged 7-15 years who are re-cently (within a month) diagnosed with type 1 diabetes at the Children's and Adolescents' Unit of HUH at the New Children's Hospital and Jorvi Hospital\n\nExclusion Criteria:\n\n* Addison's disease\n* Renal failure\n* Untreated coeliac disease\n* Untreated thyroid disorder\n* Poorly controlled asthma, per investigator judgment.\n* Unresolved adverse skin conditions in the area of sensor placement (e.g. pso-riasis, rash, Staphylococcus infection).\n* Participating in an investigational study (drug or device) wherein he\u002Fshe has received treatment from an investigational study drug or device in the last 2 weeks before enrollment into this study, as per investigator judgment.","7 Years","16 Years",{"count":193,"type":21},100,[24],"The purpose of this study is to investigate the effect of early initiated automated insulin de-livery (AID) treatment in type diabetes in children aged 7-16 years to glycemic control, diabe-tes distress of patients and caregivers, long-term micro- and macrovascular complications and cost-effectiveness compared to multiple daily injections (MDI) and continuous glucose monitoring (CGM). The immediate costs of AID therapy are higher than costs of multiple daily injection therapy, and there has been debate whether the more expensive AID therapy is justified. No research on the cost-effectiveness of AID use in children has been conducted so far in Finland, and there is generally very little research data on the long-term treatment of type 1 diabetes with AID systems. AID therapy has been studied from the point of diagno-sis of type 1 diabetes in two centers (USA and the UK) but from the perspective of maintain-ing subject's own insulin secretion. A long-term randomized and controlled study on the out-comes and cost-effectiveness of AID therapy, started from diagnosis of diabetes, is essential to create evidence-based data for optimizing current treatment recommendations.\n\nOur hypothesis is that AID treatment keeps the glycemic outcomes in targets in the long term and decreases diabetes distress. During longer time, AID system decreases the amount of micro- and macrovascular complications and is cost-effective treatment for children with type 1 diabetes (CwT1D).",[197],"Type 1 Diabetes",[199,200],"type 1 diabetes","Automated insulin delivery system","2026-03-13",{"date":203,"type":36},"2026-03-17",{"date":205,"type":21},"2026-04-01",{"date":207,"type":21},"2028-12-31",{"name":42,"class":43},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":216,"sex":17,"minAge":18,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":44},"100628509","phase-1-kf20251-trial-ketamine-cannabidiol-and-cobicistat-interaction-study-100628509","NCT07462559","KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study","KF2025#1","Inclusion Criteria:\n\n* written informed consent\n* age 18-45 years\n* healthy\n* no indications of substance abuse\n* acceptable values in laboratory tests: hemoglobin must be at least at the lower limit of the reference range (men 134 g\u002Fl, women 117 g\u002Fl), liver values at most at the upper limit of the reference range (P -ALAT: women below 35 U\u002Fl, men below 50 U\u002Fl; P -AFOS: 35 U\u002Fl - 105 U\u002Fl; P -GT: women less than 40 U\u002Fl, men less than 60 U\u002Fl; P -Bil: less than 20 umol\u002Fl) and in other results (B -PVKT, P -Krea, P -K and P -Na) only minor values that deviate from normal values, which according to the examining physician's assessment are clinically insignificant. Drug screening (U -Huum-PS) and in women the pregnancy test (P-hCG-tot) should be negative.\n* No significant abnormalities in the ECG\n\nExclusion Criteria:\n\n* significant illness\n* mood disorder or suicidality\n* substance abuse\n* systolic blood pressure over 150 mmHg\n* conduction disorder or other significant abnormality in the ECG\n* smoking\n* regular medication, excluding contraceptives that do not contain estrogens\n* pregnancy or its planning or breastfeeding\n* less than 3 months from the previous clinical trial\n* less than 3 months since donating blood\n* significant overweight or underweight\n* difficult to find elbow veins\n* hypersensitivity to investigational drugs or excipients of medicinal products\n* use of natural products (such as St. John's wort).",true,"45 Years",{"count":219,"type":21},12,[221],"PHASE1","Ketamine is a dissociative anesthetic developed approximately 60 years ago. Both ketamine and its isomer, esketamine, have been used for over 20 years in the treatment of treatment-resistant depression. Other treatment options for this type of depression include combinations of antidepressants, other medications used in depression treatment (such as lithium), psychotherapy, electroconvulsive therapy, and repetitive transcranial magnetic stimulation. The advantage of ketamine and its stereoisomer, esketamine, over other treatment options is their rapidly emerging antidepressant effect, which becomes apparent within the first few days of treatment.\n\nKetamine is primarily metabolized by the cytochrome P450 (CYP) 3A4 enzyme, but also by the CYP2B6 and CYP2C9 enzymes. However, information on the significance of these different enzymes in ketamine metabolism is incomplete. Due to extensive first-pass metabolism, the bioavailability of orally administered ketamine varies significantly and is, on average, only 8-24%. This makes ketamine unsuitable for oral administration. In the treatment of depression, ketamine is administered as a slow intravenous infusion.\n\nThe concurrent use of medications that inhibit ketamine metabolism can significantly increase the bioavailability of orally administered ketamine. Cobicistat is a potent inhibitor of the CYP3A4 enzyme, which can significantly increase ketamine bioavailability and reduce interindividual variability by inhibiting ketamine's CYP3A4-mediated metabolism. This might enable the oral use of ketamine.\n\nCannabidiol is a cannabinoid that does not have addictive effects, but may have antidepressant and anxiolytic effects. Cannabidiol might reduce the dissociative side effects associated with ketamine treatment. Clinically, cannabidiol appears to moderately inhibit CYP enzymes in the order of potency: CYP2C19 \\> CYP2C9 \\> CYP3A \\> CYP1A2, and based on in vitro data, it also somewhat inhibits the CYP2B6 enzyme, which is involved in ketamine metabolism. However, its effect on ketamine concentrations cannot be assessed based on current knowledge.\n\nThe purpose of this study is to investigate the potential effects of cannabidiol, cobicistat, and their concurrent administration on the pharmacokinetics of orally administered ketamine. A secondary objective is to study the effect of cannabidiol on ketamine-induced side effects.\n\nStudy Methodology: This is a four-phase, randomized, open-label, crossover study involving 12 healthy volunteers. On study days, participants will receive a 56 mg oral dose of ketamine in the research facility, alternately with water, cannabidiol, cobicistat, or both cannabidiol and cobicistat. There will be at least a two-week washout period between study days.\n\nThe pharmacokinetics of ketamine and other study drugs will be investigated by taking blood samples according to a separate schedule for 11 hours after administration on the study day and the following morning. Pharmacokinetic parameters will be calculated from plasma concentrations of ketamine, cobicistat, cannabidiol, and their metabolites. The primary outcome measure is the total area under the curve (AUC0-∞) of ketamine. Additionally, the effects of the drugs on blood pressure, heart rate, and subjective adverse feeling of the study participants will be examined.",[224],"Drug Drug Interaction","2026-03-05",{"date":227,"type":36},"2026-03-10",{"date":229,"type":21},"2026-03-04",{"date":231,"type":21},"2026-12-31",{"name":42,"class":43},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":44},"100393856","does-pancreatic-stent-decrease-the-risk-of-pancreatitis-after-pancreatic-sphincterotomy-for-difficult-cannulation-100393856","NCT04408482","Does Pancreatic Stent Decrease the Risk of Pancreatitis After Pancreatic Sphincterotomy for Difficult Cannulation?","Inclusion Criteria:\n\n* Consecutive patients with naïve papilla presenting to ERCP with indication of common bile duct (CBD) cannulation will be considered to the study.\n\nExclusion Criteria:\n\n* Exclusion criteria are age below 18 years, acute pancreatitis and no consent to the study.",{"count":240,"type":21},268,[24],"The purpose of the study is to compare the risk of PEP after pancreatic sphincterotomy performed for difficult cannulation in a group of patients with and in a group of patients without placement of a prophylactic pancreatic stent. The definition of difficult cannulation is defined according to the literature.",[244],"Endoscopic Retrograde Cholangiopancreatography","2026-02-27",{"date":247,"type":36},"2026-03-03",{"date":249,"type":36},"2020-08-01",{"date":251,"type":21},"2028-09-01",{"name":42,"class":43},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":261,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":125},"100615530","dance-movement-therapy-in-the-treatment-of-adolescent-depression-100615530","NCT07293806","Dance-movement Therapy in the Treatment of Adolescent Depression","Study Protocol for a Randomised Controlled Trial of Dance-movement Therapy for Adolescents With Depression","DMT","Inclusion Criteria:\n\n* Diagnosis of medium or severe depression; BDI 16 points or more. At least 4\u002F9 symptoms of depression in K-SADS-PL interview\n\nExclusion Criteria:\n\n* Acute psychosis, psychotic depression, personality disorder, severe anorexia, substance misuse that is on a critical level","13 Years","17 Years",{"count":264,"type":21},140,[24],"The aim of this research is to measure the effectiveness of Dance movement therapy in the treatment of adolescent depression.",[268],"Depression",[270,271,272,273,274],"adolescents","depression","therapy","dance","movement","2025-12-19",{"date":277,"type":36},"2025-12-26",{"date":279,"type":36},"2022-10-01",{"date":281,"type":21},"2027-05-30",{"name":42,"class":43},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":219},"100593052","cholecystectomy-after-successful-endoscopic-common-bile-duct-stone-extraction-in-elderly-100593052","NCT07001423","ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly","COFFEE","Inclusion Criteria:\n\n* Common bile duct stones cleared after Endoscopic Retrograde Cholangio Pancreatography (ERCP)\n* Age \\>= 80 years or age 75-79 years with a Charlson Comorbidity index \\>=2\n* gallbladder in situ\n\nExclusion Criteria:\n\n* Acute Cholecystitis\n* Biliary Pancreatitis\n* Severe or moderately severe post-ERCP pancreatitis\n* Chronic pancreatitis\n* Bile duct pathology\n* Widespread malignancy\n* Unable to give consent",{"count":291,"type":21},400,[24],"The goal of this study is to compare safety and efficacy of laparoscopic cholecystectomy versus wait-and-see policy after endoscopic removal of common bile duct stones in elderly. The primary endpoint is a composite outcome: Death or major postoperative complications or recurrent biliary disease within 1 year after randomization.",[295,296,297],"Cholecystectomy, Laparoscopic","Choledocholithiasis","Cholelithiasis","2025-10-02",{"date":300,"type":36},"2025-10-07",{"date":302,"type":21},"2025-10-03",{"date":304,"type":21},"2032-08-31",{"name":42,"class":43},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":216,"sex":314,"minAge":18,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":44},"100399250","transvaginal-mesh-vs-laparoscopic-colposacropexy--study-100399250","NCT04478747","Transvaginal Mesh vs. Laparoscopic Colposacropexy- Study","Women's Apical Pelvic Organ Prolapse Treatment - a Randomized Controlled Trial Comparing Transvaginal and Laparoscopic Mesh Surgery","TVM vs LCSP","Inclusion Criteria:\n\n* Age over 18 years and capability to understand the study protocol either in Finnish or Swedish.\n* Objectively diagnosed symptomatic apical prolapse (leading apical prolapse (points C\u002FD) ≥ -2) and a history of previous POP operation including hysterectomy.\n* No need for any other concomitant operations except colporrhaphies and possible prophylactic salpingo-oophorectomy in CSP groups\n\nExclusion Criteria:\n\n* A history of serious or prolonged pain after any operation or current or previous prolonged (over 6 months) pain of any reason.\n* BMI over 40\n* Regular use of systemic corticosteroid medication.\n* Incapability to understand the study protocol.","FEMALE","99 Years",{"count":317,"type":21},318,[24],"The main objective of the study is to compare subjective efficacy of trans vaginal mesh and laparoscopic colposakropexy (CSP) in women with an apical prolapse. The CSP group is further divided into two sub-groups; one where the mesh fixation is only at the apical part of the vagina, and another where the fixation is also extended to the levator plane.\n\nThe secondary outcomes are safety (peri- and post-surgery complications, pain, erosion), objective efficacy (simplified POP-Q), and re-operation rate. Subjective outcome also includes the assessment of sexual satisfaction. Cost-effectiveness is studied by comparing both direct costs and QALYs.",[321],"Prolapse, Vaginal Vault","2025-09-19",{"date":324,"type":36},"2025-09-24",{"date":326,"type":36},"2020-07-01",{"date":328,"type":21},"2032-12",{"name":42,"class":43},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":345,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":44},"100525544","stall-vs-sole-local-wound-infiltration-in-laparoscopic-cholecystectomy-100525544","NCT06123117","STALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy","Single Transversus Abdominis Laparoscopy-guided Plane Block Combined With Local Trocar Site Ropivacaine Infiltration (STALL) vs Sole Local Wound Infiltration in LCC (Laparoscopic CholeCystectomy) - Double-blinded Randomized Controlled Trial.","STALL","Inclusion Criteria:\n\n* All patients scheduled for elective or emergency LCC, aged over 18 and able to give an informed consent.\n\nExclusion Criteria:\n\n* Age under 18 years, chronic daily opioid and\u002For pain tolerance \u002F pain threshold -modifying medication use (abuse), pregnancy, known allergy to local anesthetics, diagnosed severe coagulopathy and incapability to give informed consent for whatever reason.",{"count":339,"type":21},850,[24],"This trial is a prospective randomized superiority trial comparing sole ropivacaine based local trocar site infiltration to local infiltration combined with laparoscopic ropivacaine TAP block (STALL) in LCC.\n\nThere are only a few randomized trials comparing sole local anesthesia to additional laparoscopic TAP block in laparoscopic cholecystectomy and they have yet failed to show evidence in favor of TAP block.\n\nWe hypothesize STALL (Single Transversus Abdominis Laparoscopy-guided plane block combined with Local trocar site ropivacaine infiltration) is superior to local port site infiltration, provided that the sample size is sufficiently big.\n\nThe aim of this randomized study is to compare the efficacy of sole local anesthesia of trocar sites to STALL in LCC.",[297,343,344],"Cholecystitis","Gallbladder Cancer",[346],"laparoscopic transversus abdominis plane block","2025-09-10",{"date":349,"type":36},"2025-09-11",{"date":351,"type":36},"2024-01-16",{"date":353,"type":21},"2027-10",{"name":42,"class":43},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":216,"sex":17,"minAge":362,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":44},"100508577","emotional-bodymaps-in-pediatric-pain-patients-and-their-parents-100508577","NCT05902234","Emotional Bodymaps in Pediatric Pain Patients and Their Parents.","PedPainEmot","Inclusion Criteria:\n\n* fluency in finnish language\n\nExclusion Criteria:\n\n* none","10 Years","80 Years",{"count":365,"type":21},600,"The aims of this study are to find out how pain may alter the experience of emotions in the body in pediatric pain patients and how how their parent feel the emotions in their bodies. We are also interested how this possible effect is mediated by the duration and location of pain, mood changes or with the experience of bullying.",[368],"Pediatric Pain","2025-09-09",{"date":347,"type":36},{"date":372,"type":36},"2023-10-20",{"date":374,"type":21},"2027-12-31",{"name":42,"class":43},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":383,"maxAge":262,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":44},"100491306","sleep-pain-and-stress-in-adolescents-with-persistent-pain-100491306","NCT05677412","Sleep, Pain and Stress in Adolescents With Persistent Pain","PedPainSleep","Inclusion Criteria:\n\n* Patients aged 15-17 years with persistent (\\> 3months) pain reporting average pain intensity over 3\u002F10 on the Numerical Rating Scale (NRS).\n\nExclusion Criteria:\n\n* ongoing medication for sleep or pain.","15 Years",{"count":385,"type":21},20,[24],"The main aim is the gain information of sleep structures in adolescents with persistent pain. Also to study simple interventions to support their sleep and pain management. The main aim of this study is to test the efficacy and feasibility of suggestive presleep relaxation technique in improving sleep quality and sleep-related emotional memory processing.",[389,390],"Pain, Chronic","Sleep",{"date":392,"type":36},"2025-09-15",{"date":394,"type":36},"2023-05-23",{"date":396,"type":21},"2026-06-30",{"name":42,"class":43},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":419,"locationsCount":125},"100604908","phase-3-neoadjuvant-treatment-vs-upfront-surgery-for-left-sided-pancreatic-cancer-100604908","NCT07155629","Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","Neoadjuvant Treatment vs Upfront Surgery for Left Sided Pancreatic Cancer (LEFT-PANC) - a Study Protocol for a Prospective Randomized Multicenter Trial","LEFT-PANC","Inclusion Criteria:\n\n* Resectable left pancreatic cancer according to NCCN criteria\n* Written and informed consent\n* Age \\> 18y\n* ECOG 0-2\n* Fit for surgery\n* Fit for neoadjuvant chemotherapy\n\nExclusion Criteria:\n\n* ECOG \\> 2\n* Histology other than ductal adenocarcinoma\n* Unable to give written consent\n* \\\u003C 18y","85 Years",{"count":408,"type":21},381,[167],"Pancreatic cancer is one of the most treatment resistant malignancies, often diagnosed at a late stage and associated with poor survival. The 5-year overall survival rate remains around 10%. Prognosis is affected by multiple factors including tumor stage, biology, treatment response, and anatomical location. Distal (left-sided) pancreatic cancer, originating from the body or tail of the pancreas, accounts for approximately 20-25% of all pancreatic cancers and has been associated with worse survival than pancreatic head cancer, even when adjusted for stage. This may be due to histological, molecular, and embryological differences, and varied systemic therapy responses.\n\nNeoadjuvant chemotherapy has become increasingly important in managing pancreatic cancer. It may improve outcomes by reducing tumor size, allowing for more complete (R0) resections, treating micrometastatic disease early, and identifying patients unlikely to benefit from surgery. While neoadjuvant therapy is recommended for borderline resectable and locally advanced tumors, randomized trials have not shown benefit for patients with upfront resectable pancreatic head cancer. Importantly, no randomized controlled trials have investigated the benefit of neoadjuvant treatment specifically in patients with upfront resectable left-sided pancreatic cancer, despite its distinct biology and worse prognosis.\n\nRetrospective data suggest neoadjuvant therapy may improve survival in left-sided tumors. A recent multicenter study reported significantly longer overall survival in patients treated with neoadjuvant therapy compared to upfront surgery alone. However, prospective randomized data are lacking.\n\nThis multicenter randomized trial aims to assess whether patients with resectable left-sided pancreatic cancer benefit from neoadjuvant chemotherapy compared to upfront surgery. The study will reflect real-world clinical practice by allowing both commonly used regimens-FOLFIRINOX and Gemcitaine-Nab-paclitaxel -as neoadjuvant options. Previous studies have shown these regimens to be similarly effective, and switching between them due to toxicity or progression is feasible and does not seem to impair surgical outcomes or survival. This study aims to evaluate the benefits of neoadjuvant chemotherapy before surgery in a prospective multicenter randomized setting for resectable left-sided pancreatic cancer patients.",[412],"Pancreatic Cancer Resectable","2025-09-01",{"date":415,"type":36},"2025-09-04",{"date":413,"type":21},{"date":418,"type":21},"2030-08-31",{"name":42,"class":43},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":314,"minAge":18,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":442,"leadSponsor":443,"locationsCount":44},"100602231","phase-3-optimizing-metformin-use-in-polycystic-ovary-syndrome-100602231","NCT07120815","Optimizing Metformin Use in Polycystic Ovary Syndrome","Optimizing Metformin Use in Polycystic Ovary Syndrome - A Randomized Controlled Trial","MET-PCOS","Inclusion Criteria:\n\n* Diagnosed PCOS (According to the International evidence-based Guideline for PCOS 2023)\n* Age: 18-37 years\n* BMI: ≥ 25 and \\\u003C40 kg\u002Fm2\n* Signed informed consent and willingness to comply with the trial procedures\n* Sufficient skills in the Finnish or Swedish language\n\nExclusion Criteria:\n\n* Not meeting the criteria according to the International evidence-based Guideline for PCOS 2023)\n* Use of hormonal contraceptive during the last 3 months\n* Pregnancy\n* Breastfeeding\n* Untreated diabetes\n* Hypothyroidism\n* Hyperprolactinemia\n* Use of medications for diabetes,\n* Use of medications for high cholesterol\n* Use of medications for obesity\n* Use of medications for cortisone (per oral)\n* Hypersensitivity to metformin\n* Acute metabolic acidosis\n* Renal impairment\n* Hepatic insufficiency\n* Heart- or respiratory failure\n* Serious mental illness\n* Alcoholism\n* Investigator site staff directly involved in the conduct of the study and their family members","37 Years",{"count":430,"type":21},184,[167],"The goal of this clinical trial is to learn if a metformin dose of 1500 mg or 2250 mg per day is better to treat polycystic ovary syndrome (PCOS) in adults. It will also learn about the adverse effects of metformin. The trial aims to evaluate which metformin dose is better for:\n\n1. improving biochemical and clinical outcomes\n2. gastrointestinal side-effects\n3. mental health and quality of life\n\nParticipants will:\n\n* Be randomized to take metformin at a dose of either 1500mg or 2250mg every day for 6 months\n* Visit the clinic three times during the trial for checkups and tests\n* Answer questionnaires on menstrual cyclicity, mental health, quality of life and side-effects",[434],"Polycystic Ovary Syndrome (PCOS)",[436,437,143],"polycystic ovary syndrome","metformin","2025-08-06",{"date":440,"type":36},"2025-08-13",{"date":413,"type":21},{"date":207,"type":21},{"name":42,"class":43},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":216,"sex":17,"minAge":190,"maxAge":383,"enrollmentInfo":452,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":44},"100595334","methacholine-challenge-test-in-school-children-withwithout-asthma-riska-100595334","NCT07031102","Methacholine Challenge Test in School Children With\u002FWithout Asthma RISKA","RISKA: Respiratory Irritability With School Kids With\u002FWithout Asthma - Assessment of Methacholine Responsiveness in Pediatric Asthma: A Comparative Study With Healthy Controls","RISKA","Inclusion Criteria: Healthy Controls\n\n* • Aged 7-15 years, both sexes\n\n  * No diagnosis of asthma in childhood\n  * No inhaled asthma medication during the previous 2 years\n  * No wheezing or shortness of breath during the previous 2 years\n  * Written informed consent from the participant and guardian\n\nInclusion Criteria: Children with Asthma\n\n* Aged 7-15 years, both sexes\n* Physician-diagnosed asthma (ICD-10 codes J45.0\u002FJ45.1\u002FJ45.9)\n* Inhaled corticosteroid treatment for at least 6 months\n* Either:\n\n  * Well-controlled asthma (c-ACT\u002FACT score ≥20) and no clinical need to intensify medication, or\n  * Poorly controlled asthma with physician-confirmed need for intensified asthma medication\n\nExclusion Criteria:\n\n* • Premature birth before 32 gestational weeks\n\n  * Other chronic cardiopulmonary or neurological conditions affecting airways (excluding asthma)\n  * Severe underlying illness such as malignancy\n  * Beta-blocker medication\n  * Active immunological disease",{"count":453,"type":21},260,"The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed. At the study visit, a methacholine challenge test measuring airway hyperresponsiveness and an exhaled nitric oxide measurement are performed. The effect of medication intensification in asthma patients is further assessed through a telephone interview 1-2 months after the medication adjustment.",[456,457,458],"Asthma Bronchiale","Lung Function Tests","Bronchial Hyperresponsiveness",[28,460,461,462,463],"Lung function test","children","Methacholine challange test","Bronchial provocation test","2025-06-12",{"date":466,"type":36},"2025-06-22",{"date":468,"type":36},"2024-11-06",{"date":470,"type":21},"2027-12",{"name":42,"class":43},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":216,"sex":17,"minAge":479,"maxAge":191,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":489,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":125},"100570947","intervention-effectiveness-study-of-better-at-learning-beatle--digital-neuropsychological-rehabilitation-program-100570947","NCT06713863","Intervention Effectiveness Study of BEtter AT LEarning (BEATLE)- Digital Neuropsychological Rehabilitation Program","BEATLE","For inclusion, the International Classification of Diseases 10th edition (ICD-10; WHO, 2018) diagnostic criteria accompanied with Finnish Current Care Guidelines will be used as follows:\n\nDevelopmental Language Disorder Verbal reasoning skills (Verbal Reasoning Index = VCI) 1.5 standard deviations lower than average (\\\u003C 78 Index points) Intact non-verbal reasoning skills (Perceptual Reasoning Index = PRI) \\> 84 index points) Normal or fixed to normal hearing and vision Adequate skills in Finnish: Finnish either as a native language, major household language or adequate reported performance in Finnish school system.\n\nDyslexia Measured reading accuracy and comprehension two standard deviations (-2 standard deviations) lower than anticipated when the chronological age and IQ have been taken into account Normal of fixed to normal hearing and vision Adequate skills in Finnish: Finnish either as a native language, major household language or adequate reported performance in Finnish school system.\n\nMixed Developmental Disorder Wide developmental and learning difficulties (69 \\\u003C PRI \\\u003C 84, 69 \\\u003C VCI \\\u003C 84) Normal or fixed to normal hearing and vision Adequate skills in Finnish: Finnish either as a native language, major household language or adequate reported performance in Finnish school system.\n\nExclusion Criteria:\n\nAll exclusion criteria will be addressed individually. If a respondent fulfills one or more of the exclusion criteria, the respondent will be dropped out. Exclusion criteria are formed as follows:\n\nSuspicion of mild intellectual disability Both verbal and non-verbal reasoning skills more than two standard deviations lower than average (VCI \\& PRI \\\u003C 70) Weak (-2 Standard Deviations) performance on both subtests representing fluid intelligence (Wechsler's Intelligence Scale for Children IV (WISC-IV): Matrix reasoning and Picture concepts)\n\nDiagnosis of Autism Spectrum Disorder\n\nUntreated Attention-Deficit Hyperactivity Disorder\n\nUnable to adequately use a a computer and\u002For a smartphone","12 Years",{"count":481,"type":21},312,[24],"The purpose of this study is to evaluate the effectiveness of BEATLE with clinical samples of patients diagnosed with Developmental Language Disorder (DLD), Dyslexia, and Mixed Specific Developmental Disorder. A randomized controlled trial with a waitlist design will be employed. The objective is to assess potential changes in perceived self-efficacy, self-compassion, executive functioning, and attitudes toward learning as reported by the participants, their guardians (parents), and teachers. Additionally, this study aims to examine the correlation between the usage of the Digital Care Pathway (DCP) and its effectiveness.",[485,486,487,488],"Dyslexia, Developmental","Developmental Language Disorder","Specific Learning Disorder","Borderline Intellectual Functioning",[490,491,492,493,494],"eHealth","Adolescence","Intervention","Effectiveness","RCT","2025-05-05",{"date":497,"type":36},"2025-05-08",{"date":499,"type":21},"2025-05-01",{"date":501,"type":21},"2028-04",{"name":42,"class":43},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":216,"sex":17,"minAge":510,"maxAge":511,"enrollmentInfo":512,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":514,"conditions":515,"keywords":522,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":44},"100479753","development-of-motility-and-cognition-in-infants-100479753","NCT05527080","Development of Motility and Cognition in Infants","PILKE","Inclusion Criteria:\n\n* age at enrollment 5-8mos\n* typically developing\n\nExclusion Criteria:\n\n* all neurologically significant medical histories during pregnancy, at birth or postnatally\n* suspicion of developmental delay\n* suspicion or diagnosis of syndromes with neuromotor symptoms","5 Months","26 Months",{"count":513,"type":21},250,"PILKE study uses wearables for assessing motor development in infants in order to define functional growth trajectories in the normal infants and infants at risk of neurological compromise. In addition, PILKE studies correlation of early motor development to later neurocognitive development.",[516,517,518,519,520,521],"Neurodevelopmental Disorders","Developmental Delay","Development, Infant","Child Development","Cognitive Developmental Delay","Neurophysiologic Abnormality",[523,524,525,526,527],"wearable","medical wearable","human activity recognition","growth chart","neurodevelopment","2025-03-30",{"date":530,"type":36},"2025-04-03",{"date":532,"type":36},"2021-10-01",{"date":534,"type":21},"2027-12-30",{"name":42,"class":43},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":22,"phases":546,"briefSummary":548,"conditions":549,"keywords":553,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":44},"100584485","phase-2-the-effect-of-daratumumab-in-patients-with-monoclonal-gammopathy-of-renal-significance-mgrs-in-finland-100584485","NCT06889948","The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland","Daratumumab in Monoclonal Gammopathy of Renal Significance in Finland","DAMOCLES","Inclusion Criteria:\n\n1. Males or females ≥ 18 years of age\n2. Subject has provided informed consent prior to initiation of the study or subject's legally acceptable representative has provided informed consent prior to the study when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.\n3. Renal biopsy confirmed MGRS-disease\n\n   * Renal biopsy must not be older than 3 months before informed consent. However, if renal biopsy is older than 3 mo and the study team is convinced that major histological changes have not occurred, a biopsy older than that can exceptionally be accepted.\n   * Renal transplant patients are allowed\n4. Amount of proteinuria ≥ 500 mg\u002F24 h OR eGFR ≥ 20 ml\u002Fmin prior to the study\n5. Previous anticlonal treatment is allowed if deemed ineffective\n\nExclusion Criteria:\n\n1. Myeloma or systemic AL amyloidosis (smoldering myeloma sized plasma cell clone is allowed when in association with a documented MGRS condition and AHL amyloidosis and AH amyloidosis are included)\n2. Cancer that requires treatment,\n3. MGRS related to B-cell malignant disorders,\n4. Known HIV infection, active hepatitis C infection (subjects with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen or core antibody that achieve sustained virologic response (PCR negativity in HBVNh) with antiviral therapy are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on the study),\n5. Pregnancy or breastfeeding,\n6. Cyclophosphamide within 6 months of enrollment, or oral high-dose prednisone or equivalent within 6 weeks of enrollment;\n\n   * prednisone or its equivalent at a dosage of ≤10 mg daily for a condition unrelated to MGRS (e.g. asthma or gout) allowed.\n   * mycophenolate mofetil (MMF), calcineurin inhibitors (CNI) or azathioprine treated patients are eligible if proteinuria is not improving or if kidney function is declining despite treatment with these medications. Once therapy with daratumumab started, these medications need to be discontinued unless they are used as immunosuppressive medication due to renal transplantation.\n7. In patients who previously received rituximab, reconstitution of B cells (CD19 normalized, Ly-B-CD19 lab.code 8329) required.\n8. Inability to use daratumumab and to comply with the study protocol as assessed by treating nephrologist and\u002For hematologist (e.g. severe psychiatric illness, severe lung disease, known allergy to daratumumab)",{"count":545,"type":21},30,[547],"PHASE2","The goal of this clinical trial is to learn if drug daratumumab works to treat kidney diseases other than AL-amyloidosis that fall under the category of monoclonal gammopathy of renal significance (MGRS).\n\nThe main questions it aims to answer are:\n\nDoes daratumumab have an effect on the patients' renal function or the amount of proteinuria?\n\nDoes daratumumab have an effect on the hematological endpoints evaluated by minimal residual disease (MRD) and the difference between involved and uninvolved free light chain (dFLC)?\n\nAlso changes in quality of life (according to EORTC QLQ-C30) and mechanism of complement system activation are evaluated. The number of patiets with partial or very good partial hematological remission and the number of patients with adverse events related to daratumumab are also recorded.",[550,551,552],"Kidney Failure","Paraproteinemias","Glomerulonephritis",[554,555],"Monoclonal gammopathy of renal significance","daratumumab","2025-03-17",{"date":558,"type":36},"2025-03-21",{"date":560,"type":36},"2024-01-19",{"date":562,"type":21},"2027-06",{"name":42,"class":43},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":579,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":125},"100528065","sleep-and-neuropathic-pain---intervention-study-on-pregabalin-100528065","NCT06155916","Sleep and Neuropathic Pain - Intervention Study on Pregabalin","Sleep Structure in Neuropathic Pain Patients, Psychological Factors, Brain Connectivity, and the Effect of Pregabalin on Sleep and Pain","Inclusion Criteria:\n\n* Chronic (duration \\> 3 months) painful peripheral neuropathy\n* Pain moderate to severe (NRS ≥ 4\u002F10) during the past week\n\nExclusion Criteria:\n\n* psychotic depression, clinically significant bipolar disorder\n* contraindication for performing brain fMRI (metal in the body etc)",{"count":572,"type":21},40,[24],"The goal of this clinical study is to study sleep and its microstructure in neuropathic pain patients who have or who do not have a clinically significant sleep disturbance, before and during (after 1-month stabile dosage) pregabalin treatment. To find out whether reduced pain by pregabalin associates with improved sleep quality; to study, using resting state fMRI, brain network connectivity and the volume of the choroid plexus before and during pregabalin treatment (after dosage stable for one month) at baseline and during stabile treatment with pregabalin, and to compare the usability and reliability of sleep-related information collected with sleep diaries, actigraphy, iButtons, and ambulatory polysomnography in peripheral painful neuropathy patients. The main questions it aims to answer are:\n\n* Is pregabalin more efficacious in neuropathic pain patients who suffer from insomnia compared to those with no clinically meaningful sleep disturbance?\n* Does sleep disturbance due to pain associate with brain network connectivity and may these changes be reversed by pregabalin treatment? Participants will\n* Fulfill e-questionnaires and keep sleep diary before and after 1month stabile pregabalin intervention\n* Before and after 1-month stabile pregabalin medication: 1-week Actiwatch monitoring, iButton (1 day and night), ambulatory polysomnography (1 night), brain fMRI.\n\nResearchers will compare patients with high ISI score patients to see if they benefit more from pregabalin treatment than those with low ISI score.",[576,577,578],"Neuropathic Pain","Insomnia","Sleep Disorder",[580,581,582,583,584],"polysomnography","actigraphy","fMRI","pregabalin","neuropathic pain","2025-03-11",{"date":587,"type":36},"2025-03-14",{"date":589,"type":36},"2022-11-22",{"date":591,"type":21},"2026-12",{"name":42,"class":43},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":22,"phases":603,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":613,"locationsCount":68},"100522472","protocol-based-selective-imaging-versus-routine-computed-tomography-or-ultrasound-in-suspected-appendicitis-100522472","NCT06083064","Protocol Based Selective Imaging Versus Routine Computed Tomography or Ultrasound in Suspected Appendicitis","Protocol Based Selective Imaging Versus Routine Computed Tomography or Ultrasound in Suspected Appendicitis (PROSECCO)","PROSECCO","Inclusion Criteria:\n\n\\- Suspicion of appendicitis\n\nExclusion Criteria:\n\n* Time from symptom onset over 72 hours\n* Age \\\u003C18 years\n* Pregnancy, ruled out by serum or urine HCG measurement in 18- to 49-year-old women\n* CT-scan or ultrasound already done within the last 3 days (72 hours)\n* Clinical suspicion of other disease or other reason to perform imaging study\n* Recruited earlier to the same trial",{"count":602,"type":21},900,[24],"The goal of this clinical trial is to compare protocol based selective imaging to routine imaging in adult patients with suspected appendicitis. The main question\\[s\\] it aims to answer are:\n\n* Does protocol based selective imaging using clinical scoring affect clinical outcome?\n* Does protocol based selective observation combined with score based selective imaging affect clinical outcome?\n\nParticipants will be randomized into three groups:\n\n* Selective imaging based on Adult Appendicitis Score\n* Selective observation based on Appendicitis Severity Score combined with selective imaging based on Adult Appendicitis Score\n* Routine imaging using ultrasound and\u002For computed tomography\n\nResearchers will compare selective imaging groups separately with routine imaging to see if number of negative appendectomies or number of complicated appendicitis is not significantly increased.",[606],"Appendicitis","2025-03-10",{"date":609,"type":36},"2025-03-12",{"date":611,"type":36},"2023-11-15",{"date":207,"type":21},{"name":42,"class":43},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":641},"100458150","phase-4-pre--vs-postoperative-thromboprophylaxis-in-pancreatic-surgery-100458150","NCT05245877","Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery","Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery - a Prospective, Multicenter, Randomized Controlled Trial (PREPOSTEROUS Pancreas Trial)","PREPOSTEROUS2","Inclusion Criteria:\n\nAll patients undergoing either\n\n1. pancreaticoduodenectomy or total pancreatectomy (for any indication) or\n2. distal pancreatectomy for suspicion of cancer\n\nExclusion Criteria:\n\n1. Patient on anticoagulative medication (heparin, low-molecular weight heparin, warfarin, direct oral anticoagulants) during the month (30 days) preceding surgery\n2. Emergency operation (e.g. for trauma, infection or pancreatitis)\n3. Age \\\u003C 18 years\n4. Allergy or other contraindication to planned low-molecular weight heparin\n5. Inability to give written informed consent\n6. Pancreatic resection not performed (removed from analyses after randomization)","120 Years",{"count":624,"type":21},800,[626],"PHASE4","Thromboprophylaxis for pancreatic surgery can be commenced either preoperatively or postoperatively. Despite a clear trade-off between thrombosis and bleeding in pancreatic surgery patients, there is no international consensus when thrombosis prophylaxis should be commenced in patients undergoing pancreatic surgery. There are no prospective randomized trials in this field, and current guidelines are unfortunately based on very low quality evidence, that is, a few retrospective studies and expert opinion. Both American and European thromboprophylaxis guidelines for abdominal cancer surgery support the preoperative initiation of thromboprophylaxis, but these guidelines do not specifically address the increased bleeding risk associated with pancreatic surgery. On the contrary, Dutch guidelines recommend postoperative thromboprophylaxis only, because of lack of evidence for preoperative thromboprophylaxis. Enhanced Recovery After Surgery (ERAS) Society Guidelines recommend preoperative thromboprophylaxis in pancreatic surgery, but the guidelines provide no supporting evidence for this recommendation. Overall, the amount of evidence is scarce and somewhat contradictory in this clinically relevant field of thromboprophylaxis in pancreatic surgery. The aim of this study is to compare pre- and postoperatively initiated thromboprophylaxis regimens in pancreatic surgery in a randomized controlled trial.",[629,630,116,631,632],"Pancreas Cancer","Pancreas Neoplasm","Thrombosis","Bleeding","2025-02-12",{"date":635,"type":36},"2025-02-14",{"date":637,"type":36},"2022-08-17",{"date":639,"type":21},"2026-09",{"name":42,"class":43},5,{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":22,"phases":652,"briefSummary":653,"conditions":654,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":664},"100418657","phase-4-pre--vs-postoperative-thromboprophylaxis-for-liver-resection-100418657","NCT04731558","Pre- Vs Postoperative Thromboprophylaxis for Liver Resection","Pre- Vs Postoperative Thromboprophylaxis for Liver Resection - a Prospective, Multicenter, Randomized Controlled Trial","PREPOSTEROUS","Inclusion Criteria:\n\n* All patients undergoing liver resection\n\nExclusion Criteria:\n\n* Patient on anticoagulative medication (heparin, low-molecular weight heparin, warfarin, direct oral anticoagulants) during last month pre-surgery\n* Emergency operation (e.g. for trauma or infection)\n* Age \\\u003C 18 years\n* Allergy or other contraindication to planned low-molecular weight heparin\n* Inability to give written informed consent\n* Liver resection not performed (removed from analyses after randomization)",{"count":651,"type":21},1012,[626],"Thromboprophylaxis for liver surgery can be commenced either preoperatively or postoperatively. Despite a clear trade-off between thrombosis and bleeding in liver surgery patients, there is no international consensus when thrombosis prophylaxis should be commenced in patients undergoing liver surgery. As far as we know, there are no prospective randomized trials in this field, and current guidelines are unfortunately based on very low quality evidence, that is, a few retrospective studies and expert opinion. Both American and European thromboprophylaxis guidelines for abdominal cancer surgery support the preoperative initiation of thromboprophylaxis, but these guidelines do not specifically address the increased bleeding risk associated with liver surgery. On the contrary, Dutch guidelines recommend postoperative thromboprophylaxis only, because of lack of evidence for preoperative thromboprophylaxis. Traditionally, many liver surgery units have been reluctant in using preoperative thromboprophylaxis due to the potentially increased risk of bleeding complications. Enhanced Recovery After Surgery (ERAS) Society Guidelines recommend preoperative thromboprophylaxis in liver surgery, but the guidelines provide no supporting evidence for this recommendation. Overall, the amount of evidence is scarce and somewhat contradictory in this clinically relevant field of thromboprophylaxis in liver surgery. The aim of this study is to compare pre- and postoperatively initiated thromboprophylaxis regimens in liver surgery in a randomized controlled trial.",[655,116,656,657,632],"Liver Cancer","Thrombosis, Deep Vein","Embolism, Pulmonary",{"date":635,"type":36},{"date":660,"type":36},"2021-02-10",{"date":662,"type":21},"2027-03",{"name":42,"class":43},7,""]